Case Report: Omicron BA.2 Subvariant of SARS-CoV-2 Outcompetes BA.1 in Two Co-infection Cases

Case Report: Omicron BA.2 Subvariant of SARS-CoV-2 Outcompetes BA.1 in Two Co-infection Cases

Trends from around the world suggest that the omicron BA.2 subvariant is increasing in proportion to the original BA.1 subvariant. Here we report two cases of co-infection with omicron BA.1 and omicron BA.2 in co-exposed individuals. In both individuals, genome sequencing and/or S-gene specific PCR...

Full description

Bibliographic Details
Main Authors:	Marija Gjorgjievska, Sanja Mehandziska, Aleksandra Stajkovska, Slavica Pecioska-Dokuzovska, Anica Dimovska, Idriz Durmish, Sara Ismail, Teodora Pavlovska, Antonija Stojchevska, Haris Amedi, Jasna Andonova, Marija Nikolovska, Sara Velickovikj, Zan Mitrev, Ivan Kungulovski, Goran Kungulovski
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Genetics
Subjects:	COVID-19 co-infection omicron next-generation sequencing SARS- CoV2
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.892682/full

Similar Items

Workflow for the Implementation of Precision Genomics in Healthcare
by: Sanja Mehandziska, et al.
Published: (2020-06-01)

A Pediatric Case of Glioblastoma Multiforme Associated With a Novel Germline p.His112CysfsTer9 Mutation in the MLH1 Gene Accompanied by a p.Arg283Cys Mutation in the TP53 Gene: A Case Report
by: Aleksandra Stajkovska, et al.
Published: (2019-10-01)

Trio Clinical Exome Sequencing in a Patient With Multicentric Carpotarsal Osteolysis Syndrome: First Case Report in the Balkans
by: Aleksandra Stajkovska, et al.
Published: (2018-04-01)

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
by: Alexander Wilhelm, et al.
Published: (2022-08-01)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
by: Naoyuki Miyashita, et al.
Published: (2023-05-01)

SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays
by: Alina Seidel, et al.
Published: (2023-04-01)

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
by: Carson K. L. Lo, et al.
Published: (2024-01-01)

The SARS-CoV-2 BA.2.86 subvariant: A new challenge in the ongoing pandemic
by: Prakasini Satapathy, et al.
Published: (2024-01-01)

An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
by: Meiling Zhang, et al.
Published: (2022-12-01)

Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe
by: Evangelia Georgia Kostaki, et al.
Published: (2022-12-01)

Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023
by: Jianpeng Cai, et al.
Published: (2024-12-01)

Omicron BA.2.75 Subvariant of SARS-CoV-2 Is Expected to Have the Greatest Infectivity Compared with the Competing BA.2 and BA.5, Due to Most Negative Gibbs Energy of Binding
by: Marko Popovic
Published: (2022-10-01)

Omicron-BA.1 Dispersion Rates in Mexico Varied According to the Regional Epidemic Patterns and the Diversity of Local Delta Subvariants
by: Selene Zárate, et al.
Published: (2023-01-01)

Neutralizing Antibodies against the SARS-CoV-2 Ancestral Strain and Omicron BA.1 Subvariant in Dogs and Cats in Mexico
by: Freddy Dehesa-Canseco, et al.
Published: (2023-06-01)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
by: Tomokazu Tamura, et al.
Published: (2023-07-01)

As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?
by: Ren Xu, et al.
Published: (2022-11-01)

The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection
by: Dandan Tian, et al.
Published: (2022-10-01)

Omicron subvariant BA.5 efficiently infects lung cells
by: Markus Hoffmann, et al.
Published: (2023-06-01)

Vitamin D levels and clinical outcomes of SARS-CoV-2 Omicron subvariant BA.2 in children: A longitudinal cohort study
by: Denggao Peng, et al.
Published: (2022-07-01)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
by: Carolina Torres, et al.
Published: (2023-01-01)

Case report: BA.1 subvariant showing a BA.2-like pattern using a variant-specific PCR assay due to a single point mutation downstream the spike 69/70 deletion
by: Carlos Daviña-Nuñez, et al.
Published: (2022-10-01)

Research of Epidemiologic Feature and Control of SARS-CoV-2 Omicron Subvariants BA.4 and BA.5
by: Yu WU, Jue LIU, Min LIU, Wannian LIANG
Published: (2022-10-01)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
by: Hung Fu Tseng, et al.
Published: (2023-01-01)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination1
by: Hongyu Wang, et al.
Published: (2023-12-01)

Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand
by: Kannikar Intawong, et al.
Published: (2023-12-01)

Rapid investigation of BA.4/BA.5 cases in France
by: Alain-Claude Kouamen, et al.
Published: (2022-10-01)

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies
by: Delphine Planas, et al.
Published: (2023-02-01)

Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
by: Frederik Plesner Lyngse, et al.
Published: (2022-09-01)

Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay
by: Mako Toyoda, et al.
Published: (2023-08-01)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
by: Minrun Duan, et al.
Published: (2023-12-01)

Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections
by: Iris Medits, et al.
Published: (2022-07-01)

Characteristics of the First 284 Patients Infected with the SARS-CoV-2 Omicron BA.2 Subvariant at a Single Center in the Apulia Region of Italy, January–March 2022
by: Daniela Loconsole, et al.
Published: (2022-04-01)

High Transmission Rates of Early Omicron Subvariant BA.2 in Bangkok, Thailand
by: Sininat Petcharat, et al.
Published: (2023-01-01)

Epidemiological and clinical features of children with the Omicron BA.5.2 subvariant in Guangzhou
by: Feng Li, et al.
Published: (2023-04-01)

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
by: Mingxi Li, et al.
Published: (2022-12-01)

Strong attenuation of SARS-CoV-2 Omicron BA.1 and increased replication of the BA.5 subvariant in human cardiomyocytes
by: Rayhane Nchioua, et al.
Published: (2022-12-01)

Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data
by: Yosuke Hirotsu, et al.
Published: (2022-09-01)

Iota-Carrageenan Inhibits Replication of the SARS-CoV-2 Variants of Concern Omicron BA.1, BA.2 and BA.5
by: Christian Setz, et al.
Published: (2023-07-01)

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
by: Hiam Chemaitelly, et al.
Published: (2022-06-01)

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
by: Peter J. Halfmann, et al.
Published: (2024-03-01)